-transparent.png){kind=logo}
The authors administered orally 40, 60 and 80 micrograms of Formoterol which was developed as a new bronchodilator and 4 mg of Salbutamol which is considered to be a beta 2-selective drug, to healthy adults. Pulse rate, blood pressure and blood levels of cyclic GMP, free fatty acid, cyclic AMP, glucose and lactic acid were measured in order to evaluate efficacy and dosage of Formoterol and to compare efficacy of this drug with that of Salbutamol. As a result, it is considered that Formoterol has a strong dose dependent beta 2-effect with 40 micrograms of Formoterol almost as high as 4 mg of Salbutamol in beta 2-effect. In addition, Formoterol has almost no alpha-effect and its beta 1-effect can be considered negligible in the doses of 60 micrograms and 80 micrograms.
M Yamakido, and
T Inamizu, and
T Ikuta, and
K Onari, and
M Tanabe, and
Y Nishimoto
April 1989,
The European respiratory journal,
M Yamakido, and
T Inamizu, and
T Ikuta, and
K Onari, and
M Tanabe, and
Y Nishimoto
January 1991,
Agents and actions. Supplements,
M Yamakido, and
T Inamizu, and
T Ikuta, and
K Onari, and
M Tanabe, and
Y Nishimoto
December 1982,
Xenobiotica; the fate of foreign compounds in biological systems,
M Yamakido, and
T Inamizu, and
T Ikuta, and
K Onari, and
M Tanabe, and
Y Nishimoto
January 1967,
The Journal of clinical pharmacology and the journal of new drugs,
M Yamakido, and
T Inamizu, and
T Ikuta, and
K Onari, and
M Tanabe, and
Y Nishimoto
January 1963,
The Journal of new drugs,
M Yamakido, and
T Inamizu, and
T Ikuta, and
K Onari, and
M Tanabe, and
Y Nishimoto
November 2023,
The Journal of asthma : official journal of the Association for the Care of Asthma,
M Yamakido, and
T Inamizu, and
T Ikuta, and
K Onari, and
M Tanabe, and
Y Nishimoto
August 1964,
Clinical medicine (Northfield, Ill.),
M Yamakido, and
T Inamizu, and
T Ikuta, and
K Onari, and
M Tanabe, and
Y Nishimoto
January 2003,
Pulmonary pharmacology & therapeutics,
M Yamakido, and
T Inamizu, and
T Ikuta, and
K Onari, and
M Tanabe, and
Y Nishimoto
March 1990,
Chest,
M Yamakido, and
T Inamizu, and
T Ikuta, and
K Onari, and
M Tanabe, and
Y Nishimoto
December 2009,
Pulmonary pharmacology & therapeutics,
